8.1 Parenteral Nutrition Indications & Venous Access Routes

8.1 Parenteral Nutrition Indications & Venous Access Routes

Clinical Core: Parenteral nutrition (PN) is a specialized intravenous infusion of macronutrients, electrolytes, vitamins, and trace elements indicated exclusively when the gastrointestinal tract cannot safely absorb or digest adequate nutrients. Initiating PN requires careful evaluation of gastrointestinal function, baseline nutritional status, clinical acuity, and venous access anatomy. Central venous access devices must terminate at the cavoatrial junction to dilute hypertonic solutions, whereas peripheral and midline catheters are strictly limited by osmolarity ceilings to prevent chemical thrombophlebitis.

Evidence-Based Indications for Parenteral Nutrition

The fundamental clinical aphorism of nutrition support is: "If the gut works, use it." Enteral nutrition (EN) preserves gut mucosal architecture, maintains tight junctions, supports gut-associated lymphoid tissue (GALT), and prevents bacterial translocation while avoiding catheter-related bloodstream infections. Consequently, PN is indicated only when enteral access is impossible or when gastrointestinal absorptive capacity is insufficient to maintain fluid, electrolyte, and nutrient homeostasis.

Primary Clinical Indications

1. Severe Short Bowel Syndrome (SBS) with Intestinal Failure: Anatomical loss of extensive small intestine (typically residual small bowel $< 100\text{ cm}$ without a colon-in-continuity, or $< 60\text{ cm}$ with a preserved colon) resulting in malabsorption that cannot be managed by specialized oral diets, rehydration solutions, or enteral tube feeding.
2. Complete Mechanical Bowel Obstruction: Intestinal blockage secondary to peritoneal carcinomatosis, malignant pelvic masses, extensive adhesive disease, or radiation strictures where enteral feeding proximal to the obstruction results in intractable vomiting, aspiration, or bowel perforation.
3. Severe Prolonged Paralytic Ileus: Diffuse neurogenic intestinal dysmotility lasting $> 5\text{ to } 7\text{ days}$ following major abdominal or pelvic trauma, extensive retroperitoneal surgery, or severe peritonitis, in which gastric residual volumes are massive and small bowel motility is absent.
4. High-Output Enterocutaneous Fistulas (ECF): Fistulas originating in the stomach, duodenum, or proximal jejunum discharging $> 500\text{ mL/24 hr}$ where enteral tube placement distal to the fistula tract cannot be achieved or where trial enteral feeding drives fistula output to unmanageable levels ($> 1000\text{ mL/day}$), inducing electrolyte collapse.
5. Severe Intractable Vomiting or Diarrhea: Hyperemesis gravidarum refractory to antiemetics, severe chemotherapy-induced enteritis, cryptosporidiosis in advanced immunodeficiency, or high-volume secretory diarrhea exceeding $1.5\text{ to } 2.0\text{ L/day}$ refractory to antimotility and antisecretory agents.
6. Severe Gastrointestinal Graft-versus-Host Disease (GI-GVHD): High-grade intestinal GVHD (stages III–IV) characterized by extensive mucosal sloughing, severe abdominal cramping, profuse watery diarrhea ($> 1.5\text{ L/day}$), and gastrointestinal hemorrhage where luminal feeding causes severe pain and exacerbates mucosal shearing.
7. Severe Mesenteric Ischemia or Bowel Infarction: Acute compromise of superior mesenteric arterial or venous blood flow resulting in ischemic bowel necrosis. Enteral feeding is strictly contraindicated due to the risk of precipitating extensive transmural necrosis and bowel perforation.
8. Hemodynamic Instability and Shock: During active, unresuscitated shock (mean arterial pressure $< 65\text{ mm Hg}$, escalating vasopressor requirements, escalating blood lactate), the splanchnic circulation is intensely vasoconstricted. Enteral feeding under these conditions risks non-occlusive mesenteric ischemia (NOMI). However, PN is also contraindicated during acute unresuscitated shock. PN must be held until hemodynamic stabilization, fluid resuscitation, and stable or weaning vasopressor doses are achieved.

---

Timing of Parenteral Nutrition Initiation

Clinical guidelines from the American Society for Parenteral and Enteral Nutrition (ASPEN) and the Society of Critical Care Medicine (SCCM) establish distinct initiation timelines based on baseline nutritional status and surgical scheduling in this independent study resource:

+-------------------------------------------------------------------------+
|                   PATIENT NUTRITIONAL STATUS AT PRESENTATION            |
+-------------------------------------------------------------------------+
                                     |
         +---------------------------+---------------------------+
         |                                                       |
         v                                                       v
+---------------------------------+     +---------------------------------+
| WELL-NOURISHED / MILD RISK      |     | MODERATE-TO-SEVERE MALNUTRITION |
| (No preexisting malnutrition)   |     | (Documented baseline deficit)   |
+---------------------------------+     +---------------------------------+
         |                                                       |
         v                                                       v
+---------------------------------+     +---------------------------------+
| INITIATE PN AFTER 7 DAYS        |     | INITIATE WITHIN 24 TO 48 HOURS  |
| If oral/enteral intake is zero  |     | Following fluid resuscitation   |
| or severely inadequate (<50%)   |     | and hemodynamic stabilization   |
+---------------------------------+     +---------------------------------+

1. Well-Nourished Hospitalized Patients

In patients without preexisting malnutrition who cannot tolerate oral or enteral intake, PN should not be initiated immediately. Early PN in well-nourished patients confers no survival advantage and significantly increases the incidence of nosocomial bacteremia, hyperglycemia, and metabolic dysregulation. PN should be initiated after 7 days if the patient has remained unable to receive significant oral or enteral nutrients.

2. Patients with Baseline Moderate-to-Severe Malnutrition

In patients who enter the hospital with documented moderate or severe malnutrition (unintentional weight loss $> 10\%$, severe muscle wasting, poor oral intake for weeks), the metabolic reserve is already exhausted. Waiting 7 to 10 days leads to catastrophic muscle proteolysis, immune collapse, and organ failure. In these patients, PN should be initiated as soon as feasible after full resuscitation and hemodynamic stabilization, typically within 24 to 48 hours.

3. Surgical Patients and Preoperative PN

In severely malnourished patients undergoing major elective gastrointestinal surgery, preoperative PN administered for 7 to 14 days significantly reduces postoperative complications (wound dehiscence, anastomotic leaks, surgical site infections) by approximately 10%. However, administering preoperative PN for fewer than 7 days provides no clinical benefit and merely delays surgery while exposing the patient to catheter placement complications and bacteremia.

---

Venous Access Classification & Anatomical Landmarks

Parenteral solutions are divided into peripheral parenteral nutrition (PPN) and central parenteral nutrition (CPN) based on catheter tip termination and solution osmolarity:

The Critical Midline Catheter Distinction

A common clinical and examination error is confusing a midline catheter with a central venous line. A midline catheter is inserted via the basilic, cephalic, or brachial vein in the upper arm, measuring 3 to 8 inches (8 to 20 cm) in length. Its distal tip terminates in the axillary or subclavian vein.

Examination Trap: A midline catheter is NOT a central venous access device. Because the catheter tip terminates in an intermediate peripheral vein rather than the high-flow superior vena cava, it cannot receive hypertonic central PN formulations. Infusing solutions exceeding $900\text{ mOsm/L}$ through a midline catheter causes severe chemical endothelial necrosis, axillary vein thrombosis, and loss of future vascular access.

Central Venous Tip Positioning

Central PN solutions are hypertonic ($1200\text{ to } 2000+\text{ mOsm/L}$). To prevent chemical damage to the vessel wall, the catheter tip must lie within a large-caliber vessel with rapid blood flow. The anatomical gold standard is the lower third of the superior vena cava (SVC) at the cavoatrial junction (CAJ).

• Hemodynamic Dilution: Blood flow in the adult SVC is approximately $2000\text{ mL/min}$, compared to only $20\text{ to } 40\text{ mL/min}$ in peripheral forearm veins. This rapid blood flow instantly dilutes hypertonic parenteral formulations, neutralizing osmolar stress.
• Radiographic Verification: Before initiating central PN infusion through any newly placed blind catheter, tip placement must be verified radiographically (via anterior-posterior chest radiograph or intraprocedural fluoroscopy) or electrophysiologically via intracardiac electrocardiogram (ECG) technology. On chest radiography, the CAJ corresponds to 2 vertebral body units below the carina (or approximately 3 to 5 cm below the carina).

---

Comparative Profiles of Central Venous Catheters (CVC)

Selection of a central access device depends on expected duration of therapy, inpatient versus outpatient setting, risk of infection, and patient lifestyle needs:

CENTRAL VENOUS ACCESS SPECTRUM
Short-Term (Days-Weeks)       Intermediate (Weeks-Months)       Long-Term / Home PN (Months-Years)
[Non-Tunneled Percutaneous] -------> [PICC Catheter] -------> [Tunneled Cuffed] OR [Implanted Port]
  - Subclavian / IJ / Femoral          - Basilic / Cephalic     - Hickman / Broviac   - Port-a-Cath
  - High infection / dressing          - Upper arm entry        - Dacron cuff barrier - Lowest infection

1. Non-Tunneled Percutaneous Central Catheters

• Anatomy & Insertion: Inserted directly through the skin into the subclavian, internal jugular (IJ), or femoral vein.
• Clinical Use: Acute inpatient resuscitation and short-term PN ($< 14\text{ to } 21\text{ days}$).
• Insertion Site Risk Profile:
  • Subclavian Vein: Lowest rate of central line-associated bloodstream infections (CLABSI) and deep vein thrombosis (DVT); higher risk of mechanical insertion complications (pneumothorax, hemothorax, subclavian artery puncture).
  • Internal Jugular Vein: Lower mechanical risk under ultrasound guidance; higher CLABSI risk than subclavian due to proximity to oral secretions, neck mobility, and difficulty maintaining an occlusive dressing.
  • Femoral Vein: Highest risk of both CLABSI and venous thromboembolism. Guideline consensus recommends avoiding the femoral site for parenteral nutrition unless all other access routes are completely exhausted.

2. Peripherally Inserted Central Catheters (PICC)

• Anatomy & Insertion: Inserted into the deep veins of the upper arm (basilic preferred due to larger caliber and straighter pathway; cephalic or brachial secondary) and advanced until the tip reaches the SVC/CAJ.
• Clinical Use: Intermediate-duration therapy (several weeks to several months) in both inpatient and home care settings.
• Advantages: Eliminates the risk of pneumothorax or hemothorax during placement; easily placed at the bedside under ultrasound guidance; excellent preservation of central torso veins.
• Disadvantages: Higher incidence of upper extremity deep vein thrombosis (UEDVT) compared to internal jugular or subclavian lines; smaller lumen diameter increases occlusion risk with viscous 3-in-1 admixtures.

3. Tunneled Cuffed Central Catheters (Hickman, Broviac, Groshong)

• Anatomy & Insertion: The catheter is inserted into a central vein (usually internal jugular or subclavian) and then tunneled subcutaneously for 8 to 15 cm before emerging through a separate skin exit site on the anterior chest wall.
• The Dacron Cuff Mechanism: Located approximately 2 cm inside the subcutaneous tunnel is a polyester (Dacron) cuff. Within 2 to 3 weeks of placement, surrounding fibroblasts migrate into the cuff, producing dense fibrous tissue ingrowth. This tissue ingrowth serves two critical functions:
  1. Mechanical Anchoring: Secures the catheter firmly, eliminating the need for permanent external sutures.
  2. Antimicrobial Barrier: Establishes a physical seal that blocks the migration of cutaneous microorganisms along the external catheter tract into the bloodstream.
• Clinical Use: Standard of care for long-term home parenteral nutrition (HPN) and permanent intestinal failure.
• Groshong Catheter Feature: Incorporates a pressure-sensitive, three-way slit valve at the intravascular tip that remains closed when not in use. This valve prevents blood reflux and air embolism, allowing the catheter to be flushed with normal saline alone rather than requiring heparin lock solutions.

4. Totally Implanted Ports (Port-a-Cath)

• Anatomy & Insertion: Consists of an injection reservoir (port) made of titanium or plastic with a self-sealing silicone septum, connected to a central catheter. The reservoir is surgically implanted in a subcutaneous pocket on the upper chest wall.
• Access Technique: Accessed through intact skin using a specialized non-coring needle (Huber needle) with a deflected bevel. Standard hypodermic needles must never be used to access an implanted port because they core out microscopic fragments of the silicone septum, causing permanent port leakage.
• Clinical Use: Ideal for patients requiring long-term intermittent or cyclic therapy (e.g., oncology patients receiving cyclical chemotherapy and PN, or patients who require PN 3 to 5 nights per week). When de-accessed, the skin is completely intact, allowing the patient to swim, bathe, and engage in unrestricted physical activity without external dressings.
• Infection Profile: Lowest rate of catheter-related bloodstream infections among all central venous access modalities when not accessed.